Comparison of the effectiveness of ranibizumab monotherapy vs. combined panretinal photocoagulation on the regression of neovascularization in proliferative diabetic retinopathy.

Yuqing Wang, Lin Wang, Zhi Zheng, Jiajun Xu, Zhaode Zhang

Abstract read

In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuqing WangDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Lin WangEye Hospital, The First Hospital Affiliated of Harbin Medical University, Harbin, Heilongjiang, China.

Zhi ZhengDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Jiajun XuDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Zhaode ZhangDepartment of Ophthalmology, Ningde Clinical Medical College of Fujian Medical University, Ningde Municipal Hospital, Ningde, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimal treatment strategy for proliferative diabetic retinopathy (PDR) remains an area of active investigation. This study aimed to compare the effectiveness of ranibizumab monotherapy vs. ranibizumab combined with panretinal photocoagulation (PRP) on neovascularization regression in PDR. Methods: This retrospective study analyzed 238 patients with PDR treated between January 2019 and December 2023. Patients were classified into a monotherapy group ( Results: At 24 months, the proportion of patients with residual neovascularization on the disc (NVD) was significantly lower in the combined PRP group (8.85%) than in the monotherapy group (23.20%, Conclusion: For PDR, ranibizumab combined with PRP was associated with greater NVD regression, reduced treatment burden, and a lower risk of sight-threatening complications compared with ranibizumab monotherapy, while visual and anatomical outcomes were comparable between the two groups.

Indexed as

diabetic retinopathyneovascularizationphotocoagulationranibizumabtreatment outcome

Identifiers

PMID42131595

DOI10.3389/fmed.2026.1808957

PMCPMC13160822

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.